Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 in advanced liver cancer
NCT05698459Phase 1Recruiting
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- May 2023
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OH2 in hepatocellular carcinoma (HCC), sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 3 weeks and Maximum Tolerance Dose at 2 years. Started May 2023; status: recruiting.
02
Drugs
OH2
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05698459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698459.